Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

NCT07075016 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT07075016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07075016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 3
Overall status
Recruiting
Start date
August 5, 2025
Completion date
March 31, 2029
Enrollment
227 (estimated)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia